Építés alatt – nem éles oldal
Belépés
Visszavonva4. fázis

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

A legfontosabb adatok

Ki végzi
Aytu BioPharma, Inc.
Hol
Las Vegas (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
4. fázis
Kezdés
2019. máj.
Befejezés
2025. szept. 5.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • ADZENYS XR-ODT
  • Placebo Oral Tablet
A regiszteradat frissítve
2025. október 3.
Miért állt le
Enrollment never started

Ki vehet részt

Életkor
4 év – 5 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject meets DSM-5 criteria for ADHD, combined, hyperactive/impulsive, or inattentive presentation made during a clinical interview by an experienced clinician and confirmed with the K-SADS-PL
  • Subject has an age- and sex-adjusted rating of ≥90th percentile Total Score on the ADHD RS-IV Preschool Version (rated over past 6 months)
  • Subject has a score of ≥4 on the CGI-S at Visit 2 (Baseline)
  • Subject has had symptoms consistent with ADHD for at least 6 months
  • Subject has a Peabody Picture Vocabulary Test, 4th edition Standard Score of ≥70 at Visit 1 (Screening Visit)
  • Subject has undergone an adequate course of nonpharmacological treatment for ADHD based on investigator judgment or the investigator considers the subject's condition severe enough to enroll without undergoing prior nonpharmacological treatment. Subjects who have been on a previous pharmacological treatment for ADHD may be enrolled provided they meet other entrance criteria
  • Subject has participated in structured group activity (e.g., preschool, daycare, camp) for at least 1 month that in the investigator's opinion allows assessment of symptoms and impairment in a setting outside of the home

Ki nem vehet részt

  • Taking disallowed medications
  • Other psychiatric diagnoses
  • Significant cognitive impairment
  • Chronic medical illnesses
  • Structural cardiac defects
  • Subject has a history of chronic vocal or motor tics or Tourette's syndrome or a family history of Tourette's syndrome
  • Subject's biological parent has a history of bipolar disorder
  • A parent/caregiver or someone living in the subject's home has a current or recent (past 12 months) history of substance abuse
  • Subject has history of or presence at Screening of long QT syndrome or QTc greater than 450 msec at Screening (using Fridericia's formula: QTcF) or any other clinically significant 12-lead ECG abnormality
  • Subject has a height or a weight less than or equal to the 5th percentile for age and sex at the Screening Visit
  • Subject's blood pressure measurements exceed the 95th percentile for age, sex, and height at the Screening Visits (Visit 1) and/or Baseline Visit (Visit 2) per the American Academy of Pediatrics 2017 updated guidance
  • Significant abnormal lab tests
  • Subject has history or presence of suicidal ideation, significant self-injurious behavior, or violent behavior
  • Subject shows evidence of current physical, sexual, or emotional abuse

Helyszínek itt: Egyesült Államok

  • Center for Psychiatry and Behavioral Medicine IncLas Vegas, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.

A vizsgálat 2 csoportja

  • ADZENYS XR-ODTA vizsgált kezelés

    Subjects will be assigned to receive ADZENYS XR-ODT orally disintegrating tablets in a randomized manner. Subjects will receive their dose once daily in the morning. All subjects will begin taking ADZENYS XR ODT 3.1 mg per day the morning after qualifying at Visit 2. The dose for each subject will be titrated in a stepwise fashion each week through Week 6 (Visit 8) based on the investigator's judgment of subject's clinical response (i.e., efficacy and tolerability) to 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, up to 18.8 mg once daily, until an optimal dose or the highest dose is reached. No subject will receive a dose higher than 18.8 mg/day. Doses will comprise 1 or 2 tablets to achieve the (rounded) assigned dose. Once subjects reach an optimal dose of study drug, they will continue that dose for the remainder of the study.

  • PlaceboPlacebo, összehasonlításként

    Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.

    Kezelés: Placebo Oral Tablet

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-blind, Parallel, Placebo-controlled, Flexible-dose Study of ADZENYS XR-ODT™ in Children Aged 4 to Less Than 6 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
A regiszteradat frissítve
2025. október 3.